

Legal Division  
Pfizer Inc  
235 East 42nd Street  
New York, NY 10017  
Tel 212 733 1870 Fax 646 563 9662  
Email michael.g.mahoney@pfizer.com



March 31, 2010

**Michael G. Mahoney**  
Assistant General Counsel  
Environment, Health and Safety

**BY CERTIFIED MAIL/RETURN RECEIPT**

Steven Reynolds  
Director  
U.S. Nuclear Regulatory Commission  
Division of Nuclear Material Safety  
2443 Warrenville Road STE 210  
Lisle, IL 60532-4352

Pharmacia Corporation  
C/o Kevin Sharkey, Senior Advisor  
Environment, Health & Safety, Pfizer Inc  
700 Chesterfield Parkway West, BB3K  
Chesterfield, MO 63017

Re: Financial Assurance Demonstration for Pharmacia Corporation (Chesterfield, MO and St. Louis, MO)  
Mail Zone BB3G, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017  
License #24-32439-01

Dear Mr. Reynolds and Mr. Sharkey:

Pfizer Inc is writing on behalf of Pharmacia Corporation to inform you that it may not be able to use a parent company guarantee and financial test to meet the above-referenced financial assurance requirement this year and to request appropriate relief. Due to accounting complexities arising from Pfizer Inc's acquisition of Wyeth in 2009, we are continuing to complete our review of our financial statements for the fiscal year ended December 31, 2009 to determine whether the financial test can continue to be met. Because that review is on-going, we request an extension of time to submit the documentation required by March 31, 2010 to support ongoing use of the financial test.

RECEIVED APR 06 2010


While our review of financial information is ongoing, we may not be able to meet all the requirements needed for use of the financial test at this time. We believe that any inability to use the test would result from Pfizer Inc's acquisition of Wyeth in 2009. If we determine that we do not meet the financial test now, we anticipate that in the future we will meet all the requirements for the financial test.

As of December 31, 2009, the value of the "Total assets in the United States" of Pfizer Inc and its subsidiaries was \$29,214,000,000<sup>1</sup>. In addition, Pfizer Inc's current bond rating of most recent issuance (issued 5/27/2009 and maturing 6/03/2013, 6/03/2016, 6/03/2021, and 6/03/2038) is A1 (Moody's) and AA (Standard & Poor's). Pharmacia Corporation's ultimate corporate parent is Pfizer Inc. If we determine that we do not meet the financial test, on behalf of the licensee subject to the above-referenced financial assurance requirement, we request a waiver or variance from that requirement. The corporate resources clearly exist to satisfy the environmental obligations of the licensee.

If we do not meet the financial test and the waiver or variance is not issued, an alternative form of financial assurance allowed by applicable regulations will be provided. As a precaution, we are now working to obtain such financial assurance. If it is, in fact, needed, we are attempting to put it in place, and to provide confirmation of it to you, by April 30, 2010. Due to the significant amount of work, though, to obtain such financial assurance, we may need additional time to procure it. Accordingly, if we do not meet the financial test and a waiver or variance is not granted, we request a one-month extension to provide the alternative form of financial assurance.

Please let me know if you would like to discuss any issues further.

Sincerely,



Michael G. Mahoney

Assistant General Counsel  
EHS-Legal, Pfizer Inc

---

<sup>1</sup> Represents identifiable assets only which includes net accounts & notes receivable, inventories, net fixed assets, goodwill, and net intangibles. Figure is rounded to the nearest million.